I-Anastrozole CAS 120511-73-1 API Factory High Quality
Ubonelelo lwabavelisi ngoBusulungekileyo obuPhezulu kunye noMgangatho oZinzileyo
Igama leKhemikhali: Anastrozole
CAS: 120511-73-1
Igama | Anastrozole |
Izithethantonye | I-Arimidex;α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile |
Inombolo yeCAS | 120511-73-1 |
Inombolo yeCAT | RF-API74 |
Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
Ifomula yeemolekyuli | C17H19N5 |
Ubunzima beMolekyuli | 293.37 |
Ukunyibilika | Inyibilika kwi-DMSO kunye ne-Ethanol |
Uphawu | Ruifu Chemical |
Into | Iinkcukacha |
Imbonakalo | Mhlophe ukuya kuMhlophe oMhlophe wePowder |
Isazisi A | I-IR/MS Iyahambelana nomgangatho wereferensi |
Isazisi B | I-HPLC kunye nepeak shape: Ihambelana nereferensi |
Indawo yokunyibilika | 81.0~84.0℃ |
Isiqulatho samanzi (nge-KF) | ≤0.30% |
Intsalela kwi-Ignition | ≤0.10% |
Ilahleko ekomisweni | ≤0.50% |
Iintsimbi ezinzima | ≤10ppm |
Izinto ezinxulumeneyo | |
Ukungcola A | ≤0.10% |
Ukungcola B | ≤0.20% |
Ukungcola C | ≤0.20% |
Ukungcola D | ≤0.10% |
Ukungcola E | ≤0.10% |
Ukungacoceki Okunye | ≤0.10% |
Ukungcola ngokupheleleyo | ≤0.50% |
Izinyibilikisi ezishiyekileyo | |
Cyclohexane | ≤0.30% |
I-Ethyl Acetate | ≤0.50% |
Isivavanyi | 98.0% ~ 102.0% (kwisiseko esomileyo) |
Beka ubomi kwishelufa | Iinyanga ezingama-24 |
Umgangatho woVavanyo | uMgangatho woShishino;Umgangatho we-United States Pharmacopoeia (USP). |
Ukusetyenziswa | Unyango loMhlaza wamabele |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Anastrozole (i-CAS 120511-73-1), i-non-steroidal, isizukulwana sesithathu se-achiral triazole derivative ithengiswa njenge-ARIMIDEX® yi-AstraZeneca Pharmaceuticals LP1.Ngomnye wesizukulwana sesithathu se-aromatase inhibitor ekhuphisana kakhulu kunye ne-inhibitor ekhethiweyo ye-aromatase, ngaloo ndlela ivimbela ukuguqulwa kwe-testosterone kwi-estradiol kunye ne-androstenedione kwi-estrone.Ukuvinjelwa kwe-enzayimu yearomatase kwenzeka ngokukodwa ngokubophelelana kwe-aromatase kwi-hemegroup ye-cytochrome P450, ukuncipha kwe-estrogen biosynthesis kwizicubu ezijikelezayo zomzimba kunye nasebeleni.
I-Anastrozole lunyango olunyanyezelwayo jikelele kumhlaza wamabele okwinqanaba lokuqala.Njengezinye i-aromatase inhibitors, eyona mpembelelo yayo ibaluleke kakhulu yayiyingozi eyongeziweyo yokuphuka kwamathambo, apho i-anastrozole yayikhawulelwe kwixesha lonyango.Ibonakala inetyhefu encinci xa ithelekiswa nechemotherapy;nangona kunjalo, kuye kwaqatshelwa ukuba izigulane ezininzi eziphathwe nge-anastrozole ziye zakhalaza ngeempawu ezidibeneyo kunokuba zilindelwe, ngokukodwa ukuqina kwedijithali kufana ne-rheumatoid arthritis.Olunye ulingo lwezonyango lwe-anastrozole lwabasetyhini abasemva kokuya exesheni abanomhlaza wamabele eYurophu nase-United States bachaze ukuphazamiseka kwe-musculoskeletal njengeziganeko ezimbi.I-Anastrozole (i-Arimidex®) yi-inhibitor ye-aromatase evunyiweyo kwi-EU, e-US nakwamanye amazwe emhlabeni jikelele ukuba isetyenziswe njengonyango lwe-adjuvant kubasetyhini be-postmenopausal kunye nesigaba sokuqala, umdlavuza webele we-hormone receptor-positive.Ikwavunyiwe kwi-EU nakwamanye amazwe kwihlabathi jikelele ngokuqhubeka nonyango lwe-adjuvant kwabasetyhini abasele beneminyaka eyi-2-3 ye-adjuvant tamoxifen yonyango lomhlaza wamabele.